Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.

Related collections

Author and article information

Journal

Journal ID (nlm-ta): Blood

Journal ID (iso-abbrev): Blood

Journal ID (hwp): bloodjournal

Journal ID (pmc): blood

Journal ID (publisher-id): Blood

Title: Blood

Publisher: American Society of Hematology (Washington, DC )

ISSN (Print): 0006-4971

ISSN (Electronic): 1528-0020

Publication date (Print): 26 January 2017

Publication date (Electronic preprint): 28 November 2016

Publication date PMC-release: 26 January 2017

Volume: 129

Issue: 4

Pages: 424-447

Affiliations

[1 ]Department of Internal Medicine III, University of Ulm, Ulm, Germany;

[2 ]Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;

[3 ]Department of Medical and Molecular Genetics, Faculty of Life Sciences and Medicine, King’s College London, London, United Kingdom;

[4 ]Department of Biomedicine and Prevention, Università di Roma “Tor Vergata,” Rome, Italy;

[5 ]Department of Hematology/Oncology, University of Münster, Münster, Germany;

[6 ]Institut Universitaire d’Hématologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France;

[7 ]Division of Hematology, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA;

[8 ]Service d’Hématologie, Hôpital Saint-Louis, Paris, France;

[9 ]Department of Medicine, University of Chicago, Chicago, IL;

[10 ]Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;

[11 ]National Hospital Organization Nagoya Medical Center, Nagoya, Japan;

[12 ]Department of Hematology, Oncology and Hemostasis, University of Leipzig, Leipzig, Germany;

[13 ]Department of Haematology, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands;

[14 ]Department of Hematology, University Hospital La Fe, University of Valencia, Valencia, Spain;

[15 ]Hematology Department, Hospital de la Santa Creu i Sant Pau, Jose Carreras Leukemia Research Institute, Barcelona, Spain;

[16 ]Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan;

[17 ]Department of Clinical Hematology, The Alfred Hospital, Melbourne, Australia;

[18 ]Australian Centre for Blood Diseases, Monash University, Melbourne, Australia;

[19 ]Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands; and

[20 ]The Ohio State University Comprehensive Cancer Center, Columbus, OH

Article

Accession ID: PMC5291965 Pmcid ID: PMC5291965 Pmc-uid ID: 5291965 Publisher ID: 2016/733196

DOI: 10.1182/blood-2016-08-733196

PMC ID: 5291965

PubMed ID: 27895058

SO-VID: 80a655d4-a7a7-425e-8132-feb5f76648f9

History

Date received : 12 August 2016

Date accepted : 15 November 2016

Page count

Pages: 24

Custom metadata

access free

Data availability:

Comments

Comment on this article

scite_

Cited by 2,211

See all cited by